Detalhe da pesquisa
1.
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Haematologica
; 108(11): 3058-3067, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345467
2.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
3.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688395
4.
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
Am J Hematol
; 97 Suppl 2: S19-S25, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125036
5.
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Future Oncol
; 18(33): 3689-3699, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36102212
6.
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 26(3): 529-539, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31678537
7.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682002
8.
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(1): 137-144, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30081073
9.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood
; 138(18): 1768-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297826
10.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880613
11.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol
; 93(11): 1394-1401, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132965
12.
Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions.
Haematologica
; 107(9): 2016-2017, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021608
13.
Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation.
Prog Transplant
; 27(3): 246-250, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29187090
14.
Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
Br J Haematol
; 194(1): 9-10, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128228
15.
All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia.
Haematologica
; 106(9): 2300-2301, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730846
16.
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
Haematologica
; 106(1): 284-287, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32079693
17.
Cervical cancer screening in Ghana, west Africa: prevalence of abnormal cytology and challenges for expanding screening.
Int J Gynecol Pathol
; 33(2): 197-202, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24487476
18.
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Science
; 383(6682): eadi5798, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38301010
19.
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Blood Adv
; 7(16): 4291-4301, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163361
20.
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.
Leuk Lymphoma
; 64(2): 300-311, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503412